Tag archive for ‘AB Rated version of EpiPen’
Antares: Disappointing News on AB Rated Version of EpiPen (ATRS, $0.95)
Investment Perspective Teva filed a 6-K regulatory document last night that stated: “Teva received a complete response letter on February 23, 2016 relating to its epinephrine ANDA in which the FDA identified certain major deficiencies. Teva is evaluating the CRL and intends to submit a response. Due to the major nature of the CRL, Teva expects that […]